J&J earnings expected to fall; Mumbai retailers end Novartis boycott;

> Johnson & Johnson is expected to report moderately lower earnings Tuesday, due in part to the impact of a stronger U.S. dollar on its foreign sales. Report

> Prescription benefits manager Express Scripts says it is buying health insurer WellPoint's pharmaceutical benefit management subsidiaries for just under $4.68 billion. Report

> Drug retailers in Mumbai, India, ended their boycott of Novartis and its generics arm Sandoz after the companies agreed to stop selling some of their high-priced meds directly to consumers. Report

> Decision Resources found that the colorectal cancer drug market in China will more than double by 2012 to $290 million. Release

> Sun Pharma won the FDA nod to market Roxicodone, Oxycodone hydrochloride tablets used as painkillers. Report

> Pfizer plans to auction off a 364,000-square-foot building in Michigan after four years of sales attempts failed to yield a buyer. Report

> The CRO Covance has opened new clinical research offices in Santiago, Chile and Lima, Peru, both of which will support research throughout the region. Covance has also expanded its facilities in Buenos Aires, Argentina-the site of its first office in Latin America, opened in 1997. Report

> Pfizer now holds the title of the first pharma or biotech company to have its Phase I human research trials accredited for ensuring protection of human trial participants. Report

> The Wellcome Trust led a $10 million Series C round for Cell Biosciences, a Palo Alto-based provider of nanoproteomic analysis systems to life science researchers. Report

> Fisher Scientific has won a $250 million, five-year contract to supply the 600 members of the Massachusetts Biotechnology Council with lab equipment and supplies at bulk prices. Report

> Cardiome Pharma is joining up with Merck to develop a new atrial fibrillation therapy, pocketing $60 million upfront and lining up as much as $640 million more in milestones. Its stock soared 38 percent on the news. Report

> La Jolla Pharmaceuticals is on the edge of the abyss after announcing in February that it's lupus drug Riquent was a bust. Not long after that the company cut an unspecified number of jobs and said it would evaluate its strategic options. Report

> Shares of Italy's BioXell SpA went into a dive this morning when the developer said that its experimental lead therapy for overactive bladder, Elocalcitol, failed a mid-stage trial. And the developer immediately announced plans to cut costs, starting with a move to shelve drug studies. Report

And Finally... A former Merck rep is "detailing" doctors on public health initiatives for the New York City Health Department. Report